Showing results (291-300 of 395) with videos related to

Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Lancet (London, England)|February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialDavid Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2008
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancerG Gruber, B F Cole, M Castiglione-Gertsch, et al.
Journal of the National Cancer Institute|January 10, 2008
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trialPrudence Francis, John Crown, Angelo Di Leo, et al.
Eclinicalmedicine|July 15, 2024
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysisLaura Pala, Eleonora Pagan, Isabella Sala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1996
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study GroupG Marini, S Murray, A Goldhirsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trialMarianne Ewertz, Kathryn P Gray, Meredith M Regan, et al.
British Journal of Cancer|November 17, 2004
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancerJ Bernhard, D Zahrieh, A S Coates, et al.
Breast Cancer Research and Treatment|December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 studyJ Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2005
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumorM Colleoni, S Li, R D Gelber, et al.
Pageof 40